In recent clinical applications, anti-VEGF drugs have been widely applied in neovascular lesions, such as neovascular glaucoma and macular edema associated with retinal vascular diseases, such as age-related macular degeneration and diabetic retinopathy. This evidence concerns the gene VEGFA and neovascular glaucoma.